Hepcidin and Iron in Health and Disease

Abstract

Hepcidin, the iron-regulatory hormone, determines plasma iron concentrations and total body iron content. Hepcidin, secreted by hepatocytes, functions by controlling the activity of the cellular iron exporter ferroportin, which delivers iron to plasma from intestinal iron absorption and from iron stores. Hepcidin concentration in plasma is increased by iron loading and inflammation and is suppressed by erythropoietic stimulation and during pregnancy. Hepcidin deficiency causes iron overload in hemochromatosis and anemias with ineffective erythropoiesis. Hepcidin excess causes iron-restrictive anemias including anemia of inflammation. The development of hepcidin diagnostics and therapeutic agonists and antagonists should improve the treatment of iron disorders.

References 86

1. 1.

   Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW 2021. Iron deficiency. Lancet 397:233–48

   Not in our library10.1016/s0140-6736(20)32594-0 (opens in a new tab)

2. 2.

   Pantopoulos K 2018. Inherited disorders of iron overload. Front. Nutr 5:103

   Not in our library10.3389/fnut.2018.00103 (opens in a new tab)

3. 3.

   Park CH, Valore EV, Waring AJ, Ganz T. 2001. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem 276:7806–10

   Not in our library10.1074/jbc.m008922200 (opens in a new tab)

4. 4.

   Sangkhae V, Nemeth E. 2017. Regulation of the iron homeostatic hormone hepcidin. Adv. Nutr 8:126–36

   Not in our library10.3945/an.116.013961 (opens in a new tab)

5. 5.

   Ganz T, Nemeth E. 2011. Hepcidin and disorders of iron metabolism. Annu. Rev. Med 62:347–60

   Not in our library10.1146/annurev-med-050109-142444 (opens in a new tab)

6. 6.

   Kautz L, Jung G, Valore EV, 2014. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet 46:678–84

   Not in our library10.1038/ng.2996 (opens in a new tab)

7. 7.

   Sangkhae V, Fisher AL, Chua KJ, 2020. Maternal hepcidin determines embryo iron homeostasis in mice. Blood 136:2206–16

   Not in our library10.1182/blood.2020005745 (opens in a new tab)

8. 8.

   Nemeth E, Rivera S, Gabayan V, 2004. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig 113:1271–76

   Not in our library10.1172/jci20945 (opens in a new tab)

9. 9.

   Stefanova D, Raychev A, Arezes J, 2017. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood 130:245–57

   Not in our library10.1182/blood-2017-03-772715 (opens in a new tab)

10. 10.
    An essential cell-autonomous role for hepcidin in cardiac iron homeostasis · 2016

    No notice
11. 11.

    Malerba M, Louis S, Cuvellier S, 2020. Epidermal hepcidin is required for neutrophil response to bacterial infection. J. Clin. Investig 130:329–34

    Not in our library10.1172/jci126645 (opens in a new tab)

12. 12.

    Bessman NJ, Mathieu JRR, Renassia C, 2020. Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. Science 368:186–89

    Not in our library10.1126/science.aau6481 (opens in a new tab)

13. 13.

    Donovan A, Lima CA, Pinkus JL, 2005. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 1:191–200

    Not in our library10.1016/j.cmet.2005.01.003 (opens in a new tab)

14. 14.

    Taniguchi R, Kato HE, Font J, 2015. Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin. Nat. Commun 6:8545

    Not in our library10.1038/ncomms9545 (opens in a new tab)

15. 15.

    Zhang DL, Ghosh MC, Ollivierre H, 2018. Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress. Blood 132:2078–87

    Not in our library10.1182/blood-2018-04-842997 (opens in a new tab)

16. 16.

    Aschemeyer S, Qiao B, Stefanova D, 2018. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood 131:899–910

    Not in our library10.1182/blood-2017-05-786590 (opens in a new tab)

17. 17.

    Qiao B, Sugianto P, Fung E, 2012. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 15:918–24

    Not in our library10.1016/j.cmet.2012.03.018 (opens in a new tab)

18. 18.

    Nemeth E, Tuttle MS, Powelson J, 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–93

    Not in our library10.1126/science.1104742 (opens in a new tab)

19. 19.

    Billesbolle CB, Azumaya CM, Kretsch RC, 2020. Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms. Nature 586:807–11

    Not in our library10.1038/s41586-020-2668-z (opens in a new tab)

20. 20.

    Preza GC, Ruchala P, Pinon R, 2011. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J. Clin. Investig 121:4880–88

    Not in our library10.1172/jci57693 (opens in a new tab)

21. 21.

    Schwartz AJ, Das NK, Ramakrishnan SK, 2019. Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload. J. Clin. Investig 129:336–48

    Not in our library10.1172/jci122359 (opens in a new tab)

22. 22.

    Fisher AL, Babitt JL. 2022. Coordination of iron homeostasis by bone morphogenetic proteins: current understanding and unanswered questions. Dev. Dyn 251:26–46

    Not in our library10.1002/dvdy.372 (opens in a new tab)

23. 23.

    Silvestri L, Nai A, Dulja A, Pagani A. 2019. Hepcidin and the BMP-SMAD pathway: an unexpected liaison. Vitam. Horm 110:71–99

    Not in our library10.1016/bs.vh.2019.01.004 (opens in a new tab)

24. 24.

    Canali S, Zumbrennen-Bullough KB, Core AB, 2017. Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 129:405–14

    Not in our library10.1182/blood-2016-06-721571 (opens in a new tab)

25. 25.

    Canali S, Wang CY, Zumbrennen-Bullough KB, 2017. Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6. Am. J. Hematol 92:1204–13

    Not in our library10.1002/ajh.24888 (opens in a new tab)

26. 26.

    Kautz L, Meynard D, Monnier A, 2008. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112:1503–9

    Not in our library10.1182/blood-2008-03-143354 (opens in a new tab)

27. 27.

    Kautz L, Jung G, Du X, 2015. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood 126:2031–37

    Not in our library10.1182/blood-2015-07-658419 (opens in a new tab)

28. 28.

    Wang CY, Xu Y, Traeger L, 2020. Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3. Blood 135:453–56

    Not in our library10.1182/blood.2019002620 (opens in a new tab)

29. 29.

    Artuso I, Pettinato M, Nai A, 2019. Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice. Haematologica 104:e87–90

    Not in our library10.3324/haematol.2018.199810 (opens in a new tab)

30. 30.

    Gonzalez-Fernandez D, Nemeth E, Pons EDC, 2021. INTERGROWTH-21 identifies high prevalence of low symphysis-fundal height in indigenous pregnant women experiencing multiple infections, nutrient deficiencies, and inflammation: the Maternal Infections, Nutrient Deficiencies, and Inflammation (MINDI) cohort. Curr. Dev. Nutr 5:nzab012

    Not in our library10.1093/cdn/nzab012 (opens in a new tab)

31. 31.

    Armitage AE, Eddowes LA, Gileadi U, 2011. Hepcidin regulation by innate immune and infectious stimuli. Blood 118:4129–39

    Not in our library10.1182/blood-2011-04-351957 (opens in a new tab)

32. 32.

    Kim A, Fung E, Parikh SG, 2014. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 123:1129–36

    Not in our library10.1182/blood-2013-08-521419 (opens in a new tab)

33. 33.

    Ganz T 2019. Anemia ofinflammation. N. Engl. J. Med 381:1148–57

    Not in our library10.1056/nejmra1804281 (opens in a new tab)

34. 34.

    Peters HP, Laarakkers CM, Pickkers P, 2013. Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrol. 14:70

    Not in our library10.1186/1471-2369-14-70 (opens in a new tab)

35. 35.

    Zaritsky J, Young B, Gales B, 2010. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin. J. Am. Soc. Nephrol 5:1010–14

    Not in our library10.2215/cjn.08161109 (opens in a new tab)

36. 36.

    Anderson GJ, Bardou-Jacquet E. 2021. Revisiting hemochromatosis: genetic versus phenotypic manifestations. Ann. Transl. Med 9:731

    Not in our library10.21037/atm-20-5512 (opens in a new tab)

37. 37.

    Knutson MD. 2019. Non-transferrin-bound iron transporters. Free Radic. Biol. Med 133:101–11

    Not in our library10.1016/j.freeradbiomed.2018.10.413 (opens in a new tab)

38. 38.

    Cooray SD, Heerasing NM, Selkrig LA, 2018. Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report. J. Med. Case Rep 12:18

    Not in our library10.1186/s13256-017-1526-6 (opens in a new tab)

39. 39.

    Girelli D, Trombini P, Busti F, 2011. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 96:500–6

    Not in our library10.3324/haematol.2010.033449 (opens in a new tab)

40. 40.

    Girelli D, Busti F, Brissot P, 2022. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood 139:3018–29

    Not in our library10.1182/blood.2021011338 (opens in a new tab)

41. 41.

    Taher AT, Musallam KM, Cappellini MD. 2021. β-Thalassemias. N. Engl. J. Med 384:727–43

    Not in our library10.1056/nejmra2021838 (opens in a new tab)

42. 42.

    Ganz T, Jung G, Naeim A, 2017. Immunoassay for human serum erythroferrone. Blood 130:1243–46

    Not in our library10.1182/blood-2017-04-777987 (opens in a new tab)

43. 43.

    Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. 2013. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood 122:124–33

    Not in our library10.1182/blood-2012-12-471441 (opens in a new tab)

44. 44.

    Origa R, Galanello R, Ganz T, 2007. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 92:583–88

    Not in our library10.3324/haematol.10842 (opens in a new tab)

45. 45.

    Finberg KE, Heeney MM, Campagna DR, 2008. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat. Genet 40:569–71

    Not in our library10.1038/ng.130 (opens in a new tab)

46. 46.

    Heeney MM, Guo D, De Falco L, 2018. Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood 132:448–52

    Not in our library10.1182/blood-2017-03-773028 (opens in a new tab)

47. 47.

    Silvestri L, Pagani A, Nai A, 2008. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 8:502–11

    Not in our library10.1016/j.cmet.2008.09.012 (opens in a new tab)

48. 48.

    Enns CA, Jue S, Zhang AS. 2020. The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice. Blood 136:989–1001

    Not in our library10.1182/blood.2020005222 (opens in a new tab)

49. 49.

    Weiss G, Ganz T, Goodnough LT. 2019. Anemia of inflammation. Blood 133:40–50

    Not in our library10.1182/blood-2018-06-856500 (opens in a new tab)

50. 50.

    Weir MR. 2021. Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. Am. J. Nephrol 52:450–66

    Not in our library10.1159/000516901 (opens in a new tab)

51. 51.

    Babitt JL, Eisenga MF, Haase VH, 2021. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference. Kidney Int. 99:1280–95

    Not in our library10.1016/j.kint.2021.03.020 (opens in a new tab)

52. 52.

    Pergola PE, Devalaraja M, Fishbane S, 2021. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J. Am. Soc. Nephrol 32:211–22

    Not in our library10.1681/asn.2020050595 (opens in a new tab)

53. 53.
    Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach · 2018

    No notice
54. 54.

    Maes K, Nemeth E, Roodman GD, 2010. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 116:3635–44

    Not in our library10.1182/blood-2010-03-274571 (opens in a new tab)

55. 55.

    Hara M, Ando M, Tsuchiya K, Nitta K. 2015. Serum hepcidin-25 level linked with high mortality in patients with non-Hodgkin lymphoma. Ann. Hematol 94:603–8

    Not in our library10.1007/s00277-014-2255-1 (opens in a new tab)

56. 56.

    Oh ST, Talpaz M, Gerds AT, 2020. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 4:4282–91

    Not in our library10.1182/bloodadvances.2020002662 (opens in a new tab)

57. 57.

    Pietrangelo A. 2017. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica 102:1972–84

    Not in our library10.3324/haematol.2017.170720 (opens in a new tab)

58. 58.

    Diepeveen LE, Laarakkers CMM, Martos G, 2019. Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material. Clin. Chem. Lab. Med 57:864–72

    Not in our library10.1515/cclm-2018-0783 (opens in a new tab)

59. 59.

    Schaap CC, Hendriks JC, Kortman GA, 2013. Diurnal rhythm rather than dietary iron mediates daily hepcidin variations. Clin. Chem 59:527–35

    Not in our library10.1373/clinchem.2012.194977 (opens in a new tab)

60. 60.

    Ganz T, Olbina G, Girelli D, 2008. Immunoassay for human serum hepcidin. Blood 112:4292–97

    Not in our library10.1182/blood-2008-02-139915 (opens in a new tab)

61. 61.

    Beutler B, Jiang Z, Georgel P, 2006. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol 24:353–89

    Not in our library10.1146/annurev.immunol.24.021605.090552 (opens in a new tab)

62. 62.

    Zaritsky J, Young B, Wang HJ, 2009. Hepcidin—a potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol 4:1051–56

    Not in our library10.2215/cjn.05931108 (opens in a new tab)

63. 63.

    Theurl I, Aigner E, Theurl M, 2009. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 113:5277–86

    Not in our library10.1182/blood-2008-12-195651 (opens in a new tab)

64. 64.

    Bregman DB, Morris D, Koch TA, 2013. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am. J..Hematol 88:97–101

    Not in our library10.1002/ajh.23354 (opens in a new tab)

65. 65.

    Martensson J, Glassford NJ, Jones S, 2015. Urinary neutrophil gelatinase-associated lipocalin to hepcidin ratio as a biomarker of acute kidney injury in intensive care unit patients. Minerva Anestesiol. 81:1192–200

    Not in our library

66. 66.

    Prowle JR, Calzavacca P, Licari E, 2015. Combination of biomarkers for diagnosis of acute kidney injury after cardiopulmonary bypass. Ren. Fail 37:408–16

    Not in our library10.3109/0886022x.2014.1001303 (opens in a new tab)

67. 67.

    Albert C, Haase M, Albert A, 2021. Predictive value of plasma NGAL:hepcidin-25 formajoradverse kidney events after cardiac surgery with cardiopulmonary bypass: a pilot study. Ann. Lab. Med 41:357–65

    Not in our library10.3343/alm.2021.41.4.357 (opens in a new tab)

68. 68.

    Leaf DE, Rajapurkar M, Lele SS,. 2019. Iron, hepcidin, and death in human AKI. J. Am. Soc. Nephrol 30:493–504

    Not in our library10.1681/asn.2018100979 (opens in a new tab)

69. 69.
    Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients · 2018

    Not checked
70. 70.

    Jiang Y, Jiang FQ, Kong F, 2019. Inflammatory anemia-associated parameters are related to 28-day mortality in patients with sepsis admitted to the ICU: a preliminary observational study. Ann. Intensive Care 9:67

    Not in our library10.1186/s13613-019-0542-7 (opens in a new tab)

71. 71.

    Girelli D, Nemeth E, Swinkels DW. 2016. Hepcidin in the diagnosis of iron disorders. Blood 127:2809–13

    Not in our library10.1182/blood-2015-12-639112 (opens in a new tab)

72. 72.

    Casu C, Oikonomidou PR, Chen H, 2016. Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. Blood 128:265–76

    Not in our library10.1182/blood-2015-10-676742 (opens in a new tab)

73. 73.

    Schmidt PJ, Toudjarska I, Sendamarai AK, 2013. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe−/− mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Blood 121:1200–8

    Not in our library10.1182/blood-2012-09-453977 (opens in a new tab)

74. 74.

    Guo S, Casu C, Gardenghi S, 2013. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J. Clin. Investig 123:1531–41

    Not in our library10.1172/jci66969 (opens in a new tab)

75. 75.

    Ginzburg Y, Kirubamoorthy K, Salleh S, 2021. Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy. Blood 138(Suppl. 1):390

    Not in our library

76. 76.

    Richard F, van Lier JJ, Roubert B, 2020. Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers. Am. J. Hematol 95:68–77

    Not in our library10.1002/ajh.25670 (opens in a new tab)

77. 77.

    Altamura S, Schaeper U, Dames S,. 2019. SLN124, a GalNAc-siRNA conjugate targeting TMPRSS6, efficiently prevents iron overload in hereditary haemochromatosis type 1. Hemasphere 3:e301

    Not in our library10.1097/hs9.0000000000000301 (opens in a new tab)

78. 78.

    Katsarou A, Pantopoulos K. 2018. Hepcidin therapeutics. Pharmaceuticals 11:127

    Not in our library10.3390/ph11040127 (opens in a new tab)

79. 79.

    Hawula ZJ, Wallace DF, Subramaniam VN, Rishi G. 2019. Therapeutic advances in regulating the hepcidin/ferroportin axis. Pharmaceuticals 12:170

    Not in our library10.3390/ph12040170 (opens in a new tab)

80. 80.

    Kurzrock R, Voorhees PM, Casper C, 2013. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin. Cancer Res 19:3659–70

    Not in our library10.1158/1078-0432.ccr-12-3349 (opens in a new tab)

81. 81.

    Kautz L, Jung G, Nemeth E, Ganz T. 2014. Erythroferrone contributes to recovery from anemia of inflammation. Blood 124:2569–74

    Not in our library10.1182/blood-2014-06-584607 (opens in a new tab)

82. 82.

    Theurl I, Schroll A, Sonnweber T, 2011. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 118:4977–84

    Not in our library10.1182/blood-2011-03-345066 (opens in a new tab)

83. 83.

    Kovac S, Boser P, Cui Y, 2016. Anti-hemojuvelin antibodycorrects anemia caused byinappropriately high hepcidin levels. Haematologica 101:e173–76

    Not in our library10.3324/haematol.2015.140772 (opens in a new tab)

84. 84.

    Vadhan-Raj S, Abonour R, Goldman JW, 2017. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J. Hematol. Oncol 10:73

    Not in our library10.1186/s13045-017-0427-x (opens in a new tab)

85. 85.

    Cooke KS, Hinkle B, Salimi-Moosavi H, 2013. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 122:3054–61

    Not in our library10.1182/blood-2013-06-505792 (opens in a new tab)

86. 86.

    Sheetz M, Barrington P, Callies S, 2019. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br. J. Clin. Pharmacol 85:935–48

    Not in our library10.1111/bcp.13877 (opens in a new tab)

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.